ASHBURN, Va., March 13 /PRNewswire-FirstCall/ -- Innocoll, Inc., a privately-held biopharmaceutical company, announced that the second of a series of planned phase 2 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the management of post-operative pain, has commenced dosing.
Innocoll's BUPIVACAINE SURGICAL IMPLANT is a biodegradable and fully bioresorbable matrix of purified fibrillar collagen impregnated with the local anesthetic, bupivacaine, which has been specifically developed and formulated using Innocoll's proprietary CollaRx sponge technology. It is under development in the US and Europe for the management of post-operative pain following moderate/major abdominal, gynecological, abdominal, thoracic, and orthopedic surgeries.
Post-operative pain is typically controlled with narcotic analgesics
such as morphine, but systemic administration of these drugs can result in
unfavorable side effects including suppression of breathing, sedation,
nausea and vomiting, and can also affect patient recovery. Innocoll's
BUPIVACAINE SURGICAL IMPLANT is intended to provide pain control directly
at the surgical site and thus reduce the level of additional analgesia
required following surgery. The collagen matrix naturally biodegrades over
a few days and the bupivacaine is released to provide local analgesia for
up to 96 hours post- operatively. A key feature of Innocoll's product is
the ability to implant it directly into the surgical cavity and at
different layers within the wound, such as across the peritoneum incision
and directly below the skin incision, which enables localized treatment of
both the incisional and deep, visceral pain components normally associated
with moderate and major surgery. The bioresorbable nature of the collagen
matrix also offers significant clinical benefits and convenience advantages
over ambulatory infusion pumps often used to pro
|SOURCE Innocoll, Inc.|
Copyright©2008 PR Newswire.
All rights reserved